Parliamentary Search

1-4 of 4 results for subject:Favipiravir

Show detailed: On Off
Results: 10 20 50 100
Sort by: Newest first Oldest first
Correspondence from the Parliamentary Under-Secretary of State for Public Health and Prevention relating to a contingent liability in respect of the provision and use of Favipiravir
Type
Select Committee written evidence; Parliamentary committees
Committee
Committee of Public Accounts
Date
29 June 2026
House
House of Commons
Favipiravir (FAVI) – Contingent Liability

The UK Health Security Agency (UKHSA) is receiving a supply of doses of the antiviral medicine favipiravir (FAVI) from the Government of Japan to support the United Kingdom’s preparedness and response to Hantavirus.

Favipiravir is not currently licensed for use in the United Kingdom. In line with standard international practice for...
Member
Sharon Hodgson (Labour)
Department
Department of Health and Social Care
Type
Written statements
Date
18 May 2026
Reference
HCWS30
House
House of Commons
Department of Health and Social Care Minute, dated 18 May 2026, concerning the notification of a contingent liability relating to Favipiravir
Laid by
Mrs Sharon Hodgson
Department
Department of Health and Social Care
Type
Unprinted command papers
Date
18 May 2026
Reference
2026-27
House
House of Commons; House of Lords
Favipiravir (FAVI) – Contingent Liability

My Honourable Friend the Parliamentary Under-Secretary of State for Public Health and Prevention (Sharon Hodgson MP) has made the following statement:

The UK Health Security Agency (UKHSA) is receiving a supply of doses of the antiviral medicine favipiravir (FAVI) from the Government of Japan to support the United Kingdom’s preparedness and...
Member
Baroness Merron (Labour)
Department
Department of Health and Social Care
Type
Written statements
Date
18 May 2026
Reference
HLWS33
House
House of Lords